Latest Period
Q2 2026
Security Snapshot
enGene Holdings Inc. - Common Shares (ENGN) Institutional Ownership
CUSIP: 29286M105
13F Institutional Holders and Ownership History from Q4 2023 to Q2 2026
Institutions Reporting
5
Shares (Excl. Options)
11,510,703
Price
$1.73
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Shares
- Symbol
- ENGN on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 11,510,703
- Total 13F value
- $19,913,516
- Portfolio coverage rank
- 0%
- Share change
- -44,225,626
- Value change
- -$302,294,231
- Number of holders
- 5
- Shares outstanding
- 69,067,097
- SEC-reported price per share
- $1.73
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
2 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- ENGN - enGene Holdings Inc. - Common Shares is tracked under CUSIP 29286M105.
- 5 institutions reported positions in Q2 2026.
- 9 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 59 to 5 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $380,008,010 to $19,913,516.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 5 institutions filings for Q2 2026.
Security key
29286M105
Latest holder period
Q2 2026
13F holders
5
13D/G owners
9
CIK / CUSIP context first
Open Q2 2026 holders
ENGN full holder history
enGene Therapeutics Inc. SEC filings
enGene Therapeutics Inc. company facts
enGene Therapeutics Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 29286M105:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
9
Security
ENGN
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| PERCEPTIVE ADVISORS LLC | 10% | 0% | $11,936,659 | +$223,513 | 6,899,803 | +1.9% | Perceptive Advisors LLC | 30 Jun 2026 |
| BML Investment Partners, L.P. | 10% | +27% | $45,088,578 | +$9,767,578 | 6,669,908 | +28% | BML Investment Partners, L.P. | 12 May 2026 |
| Invus Global Management, LLC | 7.8% | +25% | $35,511,355 | +$6,818,136 | 5,253,159 | +24% | Raymond Debbane | 31 Mar 2026 |
| Deep Track Capital, LP | 6.7% | +58% | $30,048,631 | +$14,462,734 | 4,317,332 | +93% | Deep Track Capital, LP | 11 Nov 2025 |
| ACORN BIOVENTURES, L.P. | 5% | $22,695,226 | 3,357,282 | Anders Hove | 20 Jul 2026 | |||
| Fonds de solidarite des travailleurs et des travailleuses du Quebec | 4.5% | $8,119,004 | 2,029,751 | Fonds de solidarite des travailleurs et des travailleuses du Quebec | 30 Sep 2024 | |||
| Adage Capital Management, L.P. | 3% | $6,115,072 | 1,528,768 | Adage Capital Management, L.P. | 31 Dec 2024 | |||
| Kynam Capital Management, LP | 2.2% | -76% | $12,510,485 | -$29,339,989 | 1,492,898 | -70% | Kynam Capital Management, LP | 31 Dec 2025 |
| BIOTECHNOLOGY VALUE FUND L P | 1.8% | -68% | $3,781,608 | -$8,424,148 | 945,402 | -69% | BVF PARTNERS L P/IL | 27 Jan 2025 |
As of 30 Jun 2026, 5 institutional investors reported holding 11,510,703 shares of enGene Holdings Inc. - Common Shares (ENGN). This represents 17% of the company’s total 69,067,097 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
17%
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
11
Latest
Q2 2026
Rows shown
1-11 of 11
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 11,510,703 | $19,913,516 | -$302,294,231 | $1.73 | 5 |
| 2026 Q1 | 55,801,630 | $380,008,010 | -$36,332,966 | $6.81 | 59 |
| 2025 Q4 | 58,699,543 | $530,008,548 | +$166,162,647 | $9.03 | 57 |
| 2025 Q3 | 40,858,497 | $279,063,473 | +$5,402,489 | $6.83 | 37 |
| 2025 Q2 | 40,420,485 | $147,130,372 | -$1,920,470 | $3.64 | 37 |
| 2025 Q1 | 40,941,351 | $183,416,794 | -$6,334,706 | $4.48 | 31 |
| 2024 Q4 | 41,304,528 | $274,675,480 | +$47,869,542 | $6.65 | 34 |
| 2024 Q3 | 34,293,391 | $227,693,885 | +$6,723,051 | $6.60 | 30 |
| 2024 Q2 | 32,608,601 | $307,109,469 | -$7,912,013 | $9.43 | 30 |
| 2024 Q1 | 31,657,538 | $536,055,932 | +$295,887,521 | $16.95 | 31 |
| 2023 Q4 | 14,187,864 | $130,941,207 | +$50,843,719 | $9.23 | 11 |